<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-28T02:55:31Z</responseDate><request verb="GetRecord" identifier="oai:kostu-rdlopen.rawdatalibrary.net:kostu/10247" metadataPrefix="oai_dc">https://kostu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:kostu-rdlopen.rawdatalibrary.net:kostu/10247</identifier><datestamp>2026-10-27T23:53:11Z</datestamp><setSpec>openaire</setSpec><setSpec>com_kostu_10000</setSpec><setSpec>col_kostu_10001</setSpec><setSpec>com_kostu_10007</setSpec><setSpec>col_kostu_10059</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Multifunctional anti-Alzheimer's agents: Synthesis, biological evaluation, and molecular docking study of new 2-phenoxyacetamide/3-phenoxypropanamide/4-oxobutanamide derivatives</dc:title><dc:creator>Shakila, Shakila</dc:creator><dc:creator>Kilic, Burcu</dc:creator><dc:creator>Bardakkaya, Merve</dc:creator><dc:creator>Aksakal, Fatma</dc:creator><dc:creator>Sagkan, Rahsan Ilikci</dc:creator><dc:creator>Dogruer, Deniz S.</dc:creator><dc:subject>Alzheimer's disease</dc:subject><dc:subject>Cholinesterase inhibitory activity</dc:subject><dc:subject>Molecular docking</dc:subject><dc:subject>Multi-target-directed ligands</dc:subject><dc:subject>Neuroprotective effect</dc:subject><dc:description>In the current study, three series of new compounds were designed and synthesized through hit optimization, based on the hit compound with a structure (E)-N-(4-{[benzyl(methyl)amino]methyl}thiazol-2-yl)-3-(3,4-dimethoxyphenyl)prop‑2-enamide, which was found as a potential multifunctional anti-Alzheimer agent in our previous study. Then, the biological activities of synthesized compounds (4a-c, 13a-b and 15a-c) were evaluated. The results indicated that 4b, a 2-phenoxyacetamide derivative, exhibited good multifunctional activities. Namely, compound 4b displayed better BChE inhibition (BChE IC50 = 2.10 µM) and antioxidant activity (ORAC = 1.18 Trolox equivalents) compared to the hit compound (BChE IC50 = 14.70 µM, ORAC = 0.5 Trolox equivalents). Additionally, 4b was able to chelate all tested biometals and it also exhibited a neuroprotective effect (63 %), comparable to reference ferulic acid (77 %) while maintaining its safety upon PC12 cell line. When it comes to lowering the levels of TNF-α, NO, IL-1β, and IL-6, 4b performed better activity, relative to the other synthesized compounds. Subsequently, in silico studies such as physicochemical properties, density functional theory (DFT) computational approach and molecular docking studies were performed.</dc:description><dc:publisher>Elsevier B.V.</dc:publisher><dc:date>2024</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/kostu/10247</dc:identifier><dc:identifier>https://doi.org/10.1016/j.molstruc.2024.139106</dc:identifier><dc:identifier>0022-2860</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Molecular Structure</dc:relation><dc:rights>info:eu-repo/semantics/closedAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://kostu-rdlopen.rawdatalibrary.net/tr/items/kostu/10247</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>